Form 4 for ACAD ACADIA PHARMACEUTICALS INC
Accepted 2025-05-02 00:00:00 ET · period of report 2025-05-01 · accession 0001415889-25-011875 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-05-02 | 2025-05-01 | ACAD | Kihara James | PRINCIPAL ACCOUNTING Off | M - OptEx | — | +2,596 | 24.9K | +12% | — |
| D | 2025-05-02 | 2025-05-02 | ACAD | Kihara James | PRINCIPAL ACCOUNTING Off | S - Sale+OE | $14.60 | -1,327 | 23.5K | -5% | -$19.4K |
| D | 2025-05-02 | 2025-05-01 | ACAD | Kihara James | PRINCIPAL ACCOUNTING Off | M - OptEx | $0.00 | -2,596 | 5,192 | -33% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-05-01 | M | A | 2,596 | — | 24,853 | D | — | — | (F1) Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. |
| 2 | Common | Common Stock | 2025-05-02 | S | D | 1,327 | $14.60 | 23,526 | D | — | — | |
| 3 | Derivative | Restricted Stock Units | 2025-05-01 | M | D | 2,596 | $0.00 | 5,192 | D | — · — to — | 2,596 Common Stock | (F1) Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. (F3) The restricted stock units vest in four equal annual installments beginning May 1, 2024. |